Stratasys Ltd. reported solid operating cash flow and earnings per share in Q3 2025, showcasing the resilience of its business model amidst macroeconomic challenges. Continued focus on operational excellence and customer engagement drives growth in high-value verticals, particularly in aerospace, defense, and medical devices.

• Strong year-over-year increase in hardware sales, with notable gains in aerospace and defense sectors, including purchases from Boeing and Honeywell.
• Successful demonstration of advanced manufacturing capabilities during the U.S. Navy’s Trident Warrior 25 exercise, highlighting operational resilience and logistics efficiency.
• Strategic adoption of the H350 platform by a major pharmaceutical company signals potential growth in medical device and drug development applications.
• Expansion of customer partnerships in high-tech sectors, including a significant investment by a leading U.S. technology firm in Stratasys' F3300 systems for prototyping and production.
• The commitment to sustainability and localized manufacturing remains central to the company’s long-term growth strategy, aligning with industry trends.